HIV drug resistance in persons who inject drugs enrolled in an HIV prevention trial in Indonesia, Ukraine, and Vietnam: HPTN 074

Autoři: Philip J. Palumbo aff001;  Yinfeng Zhang aff001;  Jessica M. Fogel aff001;  Xu Guo aff002;  William Clarke aff001;  Autumn Breaud aff001;  Paul Richardson aff001;  Estelle Piwowar-Manning aff001;  Stephen Hart aff003;  Erica L. Hamilton aff004;  Ngo T. K. Hoa aff005;  Mariya Liulchuk aff006;  Latifah Anandari aff007;  Tran Viet Ha aff008;  Kostyantyn Dumchev aff009;  Zubairi Djoerban aff010;  Irving Hoffman aff011;  Brett Hanscom aff002;  William C. Miller aff012;  Susan H. Eshleman aff001
Působiště autorů: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America aff001;  Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America aff002;  Frontier Science Foundation, Amherst, NY, United States of America aff003;  Science Facilitation Department, Durham, NC, United States of America aff004;  University of North Carolina Vietnam, Hanoi, Vietnam aff005;  Gromashevsky Institute for Epidemiology and Infectious Diseases of the National Academy of Sciences of Ukraine, Kyiv, Ukraine aff006;  University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia aff007;  Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America aff008;  Ukrainian Institute of Public Health Policy, Kyiv, Ukraine aff009;  Departments of Hematology, Medical Oncology, and Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia aff010;  Department of Medicine, University of North Carolina Chapel Hill School of Medicine, Chapel Hill, NC, United States of America aff011;  Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH, United States of America aff012
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article



Persons who inject drugs (PWID) have high HIV incidence and prevalence, and may have limited access to antiretroviral therapy (ART) in some settings. We evaluated HIV drug resistance in PWID in a randomized clinical trial (HPTN 074). The study intervention included ART at any CD4 cell count with enhanced support for ART and substance use treatment.


HPTN 074 enrolled HIV-infected PWID (index participants) with viral loads ≥1,000 copies/mL and their HIV-uninfected injection-network partners in Indonesia, Ukraine, and Vietnam; the study limited enrollment of people who reported being on ART. HIV drug resistance testing and antiretroviral (ARV) drug testing were performed using samples collected from index participants at study enrollment.


Fifty-four (12.0%) of 449 participants had HIV drug resistance; 29 (53.7%) of the 54 participants had multi-class resistance. Prevalence of resistance varied by study site and was associated with self-report of prior or current ART, detection of ARV drugs, and a history of incarceration. Resistance was detected in 10 (5.6%) of 177 newly diagnosed participants. Participants with resistance at enrollment were less likely to be virally suppressed after 52 weeks of follow-up, independent of study arm.


In HPTN 074, many of the enrolled index participants had HIV drug resistance and more than half of those had multi-class resistance. Some newly-diagnosed participants had resistance, suggesting that they may have been infected with drug-resistant HIV strains. Behavioral and geographic factors were associated with baseline resistance. Baseline resistance was associated with reduced viral suppression during study follow-up. These findings indicate the need for enhanced HIV care in this high-risk population to achieve sustained viral suppression on ART.

Klíčová slova:

Antimicrobial resistance – Antiretrovirals – Drug screening – HIV epidemiology – HIV prevention – Viral load


1. Baggaley RF, Boily MC, White RG, Alary M. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS. 2006;20: 805–12. doi: 10.1097/01.aids.0000218543.46963.6d 16549963

2. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5: e1192–e207. doi: 10.1016/S2214-109X(17)30375-3 29074409

3. Wolfe D. Paradoxes in antiretroviral treatment for injecting drug users: access, adherence and structural barriers in Asia and the former Soviet Union. Int J Drug Policy. 2007;18: 246–54. doi: 10.1016/j.drugpo.2007.01.012 17689372

4. Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376: 355–66. doi: 10.1016/S0140-6736(10)60832-X 20650513

5. Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5: e1208–e20. doi: 10.1016/S2214-109X(17)30373-X 29074410

6. Bassetti S, Battegay M, Furrer H, Rickenbach M, Flepp M, Kaiser L, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 1999;21: 114–9. 10360802

7. Carrieri MP, Moatti JP, Vlahov D, Obadia Y, Reynaud-Maurupt C, Chesney M. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. J Epidemiol Community Health. 1999;53: 4–8. doi: 10.1136/jech.53.1.4 10326045

8. Lert F, Kazatchkine MD. Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview. Int J Drug Policy. 2007;18: 255–61. doi: 10.1016/j.drugpo.2007.05.002 17689373

9. Donoghoe MC, Bollerup AR, Lazarus JV, Nielsen S, Matic S. Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002–2004. Int J Drug Policy. 2007;18: 271–80. doi: 10.1016/j.drugpo.2007.02.010 17689375

10. Werb D, Mills EJ, Montaner JS, Wood E. Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis. Lancet Infect Dis. 2010;10: 464–9. doi: 10.1016/S1473-3099(10)70097-9 20610328

11. Bogart LM, Kelly JA, Catz SL, Sosman JM. Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr. 2000;23: 396–404. doi: 10.1097/00126334-200004150-00006 10866232

12. Bangsberg DR, Hecht FM, Clague H, Charlebois ED, Ciccarone D, Chesney M, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26: 435–42. doi: 10.1097/00126334-200104150-00005 11391162

13. Wood E, Hogg RS, Yip B, Dong WW, Wynhoven B, Mo T, et al. Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS. 2005;19: 1189–95. doi: 10.1097/01.aids.0000176219.48484.f1 15990572

14. Miller WC, Hoffman IF, Hanscom BS, Ha TV, Dumchev K, Djoerban Z, et al. A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study. Lancet. 2018;392: 747–59. doi: 10.1016/S0140-6736(18)31487-9 30191830

15. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375: 1014–28. doi: 10.1016/S0140-6736(10)60232-2 20189638

16. DeHovitz J, Uuskula A, El-Bassel N. The HIV epidemic in Eastern Europe and Central Asia. Curr HIV/AIDS Rep. 2014;11: 168–76. doi: 10.1007/s11904-014-0202-3 24652411

17. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2016 [cited 24 Jun, 2019]. Available from: 27466667

18. Fogel JM, Zhang Y, Palumbo PJ, Guo X, Clarke W, Breaud A, et al. Use of antiretroviral drug testing to assess the accuracy of self-reported data from HIV-infected people who inject drugs. AIDS Behav. 2019;23: 2101–2108. doi: 10.1007/s10461-018-2379-8 30600453

19. Struck D, Lawyer G, Ternes AM, Schmit JC, Bercoff DP. COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 2014;42: e144. doi: 10.1093/nar/gku739 25120265

20. Pineda-Pena AC, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K, et al. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol. 2013;19: 337–48. doi: 10.1016/j.meegid.2013.04.032 23660484

21. Siepel AC, Halpern AL, Macken C, Korber BT. A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences. AIDS Res Hum Retroviruses. 1995;11: 1413–6. doi: 10.1089/aid.1995.11.1413 8573400

22. Marzinke MA, Breaud A, Parsons TL, Cohen MS, Piwowar-Manning E, Eshleman SH, et al. The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood. Clin Chim Acta. 2014;433: 157–68. doi: 10.1016/j.cca.2014.03.016 24661980

23. Zhang Y, Clarke W, Marzinke MA, Piwowar-Manning E, Beauchamp G, Breaud A, et al. Evaluation of a multidrug assay for monitoring adherence to a regimen for HIV preexposure prophylaxis in a clinical study, HIV Prevention Trials Network 073. Antimicrob Agents Chemother. 2017;61: e02743–16. doi: 10.1128/AAC.02743-16 28438932

24. Bbosa N, Kaleebu P, Ssemwanga D. HIV subtype diversity worldwide. Curr Opin HIV AIDS. 2019;14: 153–60. doi: 10.1097/COH.0000000000000534 30882484

25. Do HT, Nguyen DT, Nguyen LAT, Do DH, Le HX, Trinh XMT, et al. An alarmingly high proportion of HIV-1 isolates carrying mutations corresponding to resistance to antiretroviral drugs among HIV-positive high-risk groups in Central Vietnam: a substudy of the National Sentinel Survey. Jpn J Infect Dis. 2017;70: 621–7. doi: 10.7883/yoken.JJID.2016.512 28890504

26. Socias ME, Nosova E, Kerr T, Hayashi K, Harrigan PR, Shoveller J, et al. Patterns of transmitted drug resistance and virological response to first-line antiretroviral treatment among human immunodeficiency virus-infected people who use illicit drugs in a Canadian setting. Clin Infect Dis. 2017;65: 796–802. doi: 10.1093/cid/cix428 28482025

27. Tanuma J, Quang VM, Hachiya A, Joya A, Watanabe K, Gatanaga H, et al. Low prevalence of transmitted drug resistance of HIV-1 during 2008–2012 antiretroviral therapy scaling up in Southern Vietnam. J Acquir Immune Defic Syndr. 2014;66: 358–64. doi: 10.1097/QAI.0000000000000196 24815852

28. Pham QD, Do NT, Le YN, Nguyen TV, Nguyen DB, Huynh TK, et al. Pretreatment HIV-1 drug resistance to first-line drugs: results from a baseline assessment of a large cohort initiating ART in Vietnam, 2009–10. J Antimicrob Chemother. 2015;70: 941–7. doi: 10.1093/jac/dku473 25433009

29. World Health Organization. HIV drug resistance prevention, surveillance and monitoring in the Western Pacific region. 2009 [cited 11 Jul, 2018]. Available from:;jsessionid=DDC9021F3BD01D756881056D3846C74F?sequence=1

30. Frentz D, van de Vijver D, Abecasis A, Albert J, Hamouda O, Jorgensen L, et al. Patterns of transmitted HIV drug resistance in Europe vary by risk group. PLoS One. 2014;9: e94495. doi: 10.1371/journal.pone.0094495 24721998

31. Yebra G, Delgado R, Pulido F, Rubio R, Galan JC, Moreno S, et al. Different trends of transmitted HIV-1 drug resistance in Madrid, Spain, among risk groups in the last decade. Arch Virol. 2014;159: 1079–87. doi: 10.1007/s00705-013-1933-y 24297490

32. Parczewski M, Leszczyszyn-Pynka M, Witak-Jedra M, Maciejewska K, Rymer W, Szymczak A, et al. Transmitted HIV drug resistance in antiretroviral-treatment-naive patients from Poland differs by transmission category and subtype. J Antimicrob Chemother. 2015;70: 233–42. doi: 10.1093/jac/dku372 25248322

33. Chang SY, Chen MY, Lee CN, Sun HY, Ko W, Chang SF, et al. Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan. J Antimicrob Chemother. 2008;61: 689–93. doi: 10.1093/jac/dkn002 18227088

34. Tossonian HK, Raffa JD, Grebely J, Viljoen M, Mead A, Khara M, et al. Primary drug resistance in antiretroviral-naive injection drug users. Int J Infect Dis. 2009;13: 577–83. doi: 10.1016/j.ijid.2008.08.028 19111493

35. Memarnejadian A, Menbari S, Mansouri SA, Sadeghi L, Vahabpour R, Aghasadeghi MR, et al. Transmitted drug resistance mutations in antiretroviral-naive injection drug users with chronic HIV-1 infection in Iran. PLoS One. 2015;10: e0126955. doi: 10.1371/journal.pone.0126955 25962088

Článek vyšel v časopise


2019 Číslo 10
Nejčtenější tento týden